Coherus Delivers With Pegfilgrastim Autoinjector Launch
New Version Of Udenyca US Neulasta Biosimilar Comes Ahead Of On-Body Device
Amid increasing competition on biosimilar pegfilgrastim in the US, Coherus is looking to bolster its position with the launch of an Udenyca autoinjector presentation, while it awaits approval for a rival to Amgen’s Neulasta Onpro on-body injector device later this year.
You may also be interested in...
Amneal Completes Hat Trick With Delayed $2.6bn US Pegfilgrastim Entry
With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.
Accord Sees Benefits From Unique Portfolio
With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.
UAE’s Bioventure Is Looking For Partners To Expand
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.